Is there a use for nesiritide in pediatric patients?

Journal of Intensive Care Medicine

Volumn 19, Issue 3, 2004, Pages 171-173

  Schamberger, Marcus S ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; GLYCERYL TRINITRATE; NESIRITIDE; PLACEBO; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; EDITORIAL; HEADACHE; HUMAN; HYPOTENSION; MEDICAL RESEARCH; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STEADY STATE; ADULT; CHILD;

ADULT; CHILD; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN;

EID: 4644249255     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066604263841     Document Type: Editorial

References (14)

1. Struthers AD. Ten years of natriuretic peptide research: a new dawn for their diagnostic and therapeutic use? BMJ. 1994;308:1615-1619.
2. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988;332:78-81.
3. DeBold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci. 1981;28:89-94.
4. Yasue H, Yoshimura H, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195-203.
5. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002;39(5):798-803.
6. Keating GM, Goa KL. Nesiritide: a review of its use in acute dccompensated heart failure. Drugs. 2003;63(1):47-70.
7. Colluci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343(4):246-253.
8. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. JAMA. 2002;287(12):1531-1540.
9. Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J. 2002;144(6):1102-1108.
10. Abraham WT, Adams KF, Fonarow GC, et al. Comparison of in-hospital mortality in patients treated with nesiritide vs other parental vasoactive medications for acutely decompensated heart failure: an analysis from a large prospective registry database. J Card Fail. 2003;9(5 suppl 1):412.
11. Chen UH, Redfield MM, Schirger JA, et al. Chronic subcutaneous administration of BNP in human heart failure for eight weeks: a pilot study to establish safety and lack of tolerance. J Card Fail. 2003;9(5 suppl 1):525.
12. Mulki GM, Pisano C, Colleen G, et al. Safety and efficacy of intermittent, short-term, outpatient nesiritide infusions for the treatment of decompensated heart failure. J Card Fail. 2003;9(5 suppl 1):559.
13. Sehra R, Underwood KR. Nesiritide improves urine output in severely ill pediatric patients awaiting heart transplantation without severe hypotension. J Card Fail. 2003;9(5 suppl 1):175.
14. Marshall J, Berkenbosch JW, Russo P, Tobias JD. Preliminary experience with nesiritide in the pediatric population. J Intenstiv Care Med. 2004;19:164-170.